Randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19
International Journal of Infectious Diseases（2022）
摘要
Upamostat was well tolerated, shortened recovery time, and decreased new severe symptoms and hospitalization.
更多查看译文
关键词
COVID-19,Clinical trial,SARS-CoV-2,Serine protease inhibitor,Upamostat
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要